Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

doi:10.1093/cvr/cvx198

Article

Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

Cardiovascular research - 1 Jan 2018

Elinoff Jason M, Chen Li-Yuan, Dougherty Edward J, Awad Keytam S, Wang Shuibang, Biancotto Angelique, Siddiqui Afsheen H, Weir Nargues A, Cai Rongman, Sun Junfeng, Preston Ioana R, Solomon Michael A, Danner Robert L

Abstract excerpt

Aims: Spironolactone (SPL) improves endothelial dysfunction and survival in heart failure. Immune modulation, including poorly understood mineralocorticoid receptor (MR)-independent effects of SPL might contribute to these benefits and possibly be useful in other inflammatory cardiovascular diseases such as pulmonary arterial hypertension. Methods and results: Using human embryonic kidney cells (HEK 293)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

Abstract excerpt

Topics

Related research